Zobrazeno 1 - 10
of 571
pro vyhledávání: '"David N. Herrmann"'
Autor:
Samira Anderson, Guido Cavaletti, Linda J. Hood, Michael Polydefkis, David N. Herrmann, Gary Rance, Brett King, Amy J. McMichael, Maryanne M. Senna, Brian S. Kim, Lynne Napatalung, Robert Wolk, Samuel H. Zwillich, Gregor Schaefer, Yankun Gong, Melanie Sisson, Holly B. Posner
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 4, Pp n/a-n/a (2024)
Abstract Reversible axonal swelling and brainstem auditory evoked potential (BAEP) changes were observed in standard chronic (9‐month) toxicology studies in dogs treated with ritlecitinib, an oral Janus kinase 3/tyrosine kinase expressed in hepatoc
Externí odkaz:
https://doaj.org/article/3530c0e1c1d5497d97bb7fe1b83e42ad
Autor:
David Michelson, William W. Chin, Robert H. Dworkin, Roy Freeman, David N. Herrmann, Ralph Mazitschek, Rodica Pop-Busui, Aziz Shaibani, James Vornov, Melissa Jones, Matthew Jarpe, Brittany Hader, Theresa Viera, Michelle Hylan, Tim Kachmar, Simon Jones
Publikováno v:
PAIN Reports, Vol 8, Iss 6, p e1114 (2023)
Abstract. Introduction:. Current treatments for painful diabetic peripheral neuropathy (DPN) are insufficiently effective for many individuals and do not treat nonpain signs and symptoms. The enzyme histone deacetylase type 6 (HDAC6) may play a role
Externí odkaz:
https://doaj.org/article/43d645a10fbd4b539890e51d56390ee1
Autor:
Katy Eichinger, Janet E. Sowden, Joshua Burns, Michael P. McDermott, Jeffrey Krischer, John Thornton, Davide Pareyson, Steven S. Scherer, Michael E. Shy, Mary M. Reilly, David N. Herrmann
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
With therapeutic trials on the horizon for Charcot-Marie-Tooth type 1A (CMT1A), reliable, valid, and responsive clinical outcome assessments and biomarkers are essential. Accelerate Clinical Trials in CMT (ACT-CMT) is an international study designed
Externí odkaz:
https://doaj.org/article/d46dcb0d9ea4402aa80c7dfef06a61b5
Refining clinical trial inclusion criteria to optimize the standardized response mean of the CMTPedS
Autor:
Kayla M. D. Cornett, Manoj P. Menezes, Paula Bray, Rosemary R. Shy, Isabella Moroni, Emanuela Pagliano, Davide Pareyson, Tim Estilow, Sabrina W. Yum, Trupti Bhandari, Francesco Muntoni, Matilde Laura, Mary M. Reilly, Richard S. Finkel, Katy J. Eichinger, David N. Herrmann, Michael E. Shy, Joshua Burns, CMTPedS Study Group
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 7, Iss 9, Pp 1713-1715 (2020)
Abstract The CMT Pediatric Scale (CMTPedS) is a reliable, valid, and responsive clinical outcome measure of disability in children with CMT. The aim of this study was to identify the most responsive patient subset(s), based on the standardized respon
Externí odkaz:
https://doaj.org/article/4e4fc26a6202461d90f33f1f848aad27
Autor:
Peter D. Creigh, Joan Mountain, Janet E. Sowden, Katy Eichinger, Bernard Ravina, Jane Larkindale, David N. Herrmann
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 6, Iss 9, Pp 1718-1727 (2019)
Abstract Objective Experimental therapies under development for Friedreich’s Ataxia (FRDA) require validated biomarkers. In‐vivo reflectance confocal microscopy (RCM) of skin is a noninvasive way to quantify Meissner’s corpuscle (MC) density an
Externí odkaz:
https://doaj.org/article/e71d50a2d5d741cb94b1bd41b5c88f06
Autor:
Mary M. Reilly, David N. Herrmann, Davide Pareyson, Steven S. Scherer, Richard S. Finkel, Stephan Züchner, Joshua Burns, Michael E. Shy
Publikováno v:
Annals of Neurology. 93:906-910
Autor:
Vera, Fridman, Stefan, Sillau, Jacob, Bockhorst, Kaitlin, Smith, Isabella, Moroni, Emanuela, Pagliano, Chiara, Pisciotta, Guiseppe, Piscosquito, Matilde, Laurá, Francesco, Muntoni, Chelsea, Bacon, Shawna, Feely, Tiffany, Grider, Laurie, Gutmann, Rosemary, Shy, Janel, Wilcox, David N, Herrmann, Jun, Li, Sindhu, Ramchandren, Charlotte J, Sumner, Thomas E, Lloyd, John, Day, Carly E, Siskind, Sabrina W, Yum, Reza, Sadjadi, Richard S, Finkel, Steven S, Scherer, Davide, Pareyson, Mary M, Reilly, Michael E, Shy
Publikováno v:
Annals of Neurology. 93:563-576
The paucity of longitudinal natural history studies in MPZ neuropathy remains a barrier to clinical trials. We have completed a longitudinal natural history study in patients with MPZ neuropathies across 13 sites of the Inherited Neuropathies Consort
Autor:
Florian P. Thomas, Thomas H. Brannagan, Russell J. Butterfield, Urvi Desai, Ali A. Habib, David N. Herrmann, Katy J. Eichinger, Nicholas E. Johnson, Chafic Karam, Alan Pestronk, Colin Quinn, Michael E. Shy, Jeffrey M. Statland, Sub H. Subramony, David Walk, Katherine Stevens-Favorite, Barry Miller, Ashley Leneus, Marcie Fowler, Marc van de Rijn, Kenneth M. Attie
Publikováno v:
Neurology
Background and ObjectivesThe goal of this work was to determine whether locally acting ACE-083 is safe and well tolerated and increases muscle volume, motor function, and quality of life (QoL) in adults with Charcot-Marie-Tooth disease (CMT) type 1.M
Autor:
Tyler Rehbein, Tong Tong Wu, Simona Treidler, Davide Pareyson, Richard Lewis, Sabrina W Yum, Brett A McCray, Sindhu Ramchandren, Joshua Burns, Jun Li, Richard S Finkel, Steven S Scherer, Stephan Zuchner, Michael E Shy, Mary M Reilly, David N Herrmann
Publikováno v:
Brain.
Recessive SH3TC2 variants cause Charcot-Marie-Tooth disease type 4C (CMT4C). CMT4C is typically a sensorimotor demyelinating polyneuropathy, marked by early onset spinal deformities, but its clinical characteristics and severity are quite variable. C
Autor:
Peter D. Creigh, Khai Du, Elizabeth P. Wood, Joan Mountain, Janet Sowden, Julie Charles, Steffen Behrens-Spraggins, David N. Herrmann
Publikováno v:
Neurology
Background and ObjectivesThe goal of this work was to establish age-, sex-, and body dimension–adjusted normal cutoff values for Meissner corpuscle (MC) densities via in vivo reflectance confocal microscopy (RCM), timed vibration sensory thresholds